Grace Therapeutics
GRCE
33 hedge funds and large institutions have $8.74M invested in Grace Therapeutics in 2026 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 11 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
3% less funds holding
Funds holding: 34 → 33 (-1)
3.9% less ownership
Funds ownership: 27.56% → 23.66% (-3.9%)
56% less capital invested
Capital invested by funds: $19.7M → $8.74M (-$11M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$694K |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
+$553K |
| 3 |
CF
Cantor Fitzgerald
New York
|
+$277K |
| 4 |
Two Sigma Investments
New York
|
+$268K |
| 5 |
BC
Birchview Capital
Burlington,
Vermont
|
+$194K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$3.37M |
| 2 |
Renaissance Technologies
New York
|
-$1.13M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$423K |
| 4 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$391K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
-$309K |
GRCE Hedge Fund Activity: Q2 2026 in Review
33 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q2 2026, worth a combined $8.74M — down 56% from $19.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GRCE and 10 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 12 added.
The largest buyer was Citadel Advisors, adding an estimated $694K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $3.37M sold.
- 33 institutional investors held Grace Therapeutics (GRCE) as of Q2 2026, down from 34 in Q1 2026.
- Funds reported $8.74M of Grace Therapeutics stock for Q2 2026, down 56% quarter-over-quarter.
- 10 funds opened new Grace Therapeutics positions in Q2 2026 and 11 closed out, a net change of -1 holder.
- The largest Grace Therapeutics buyer in Q2 2026 was Citadel Advisors, an estimated $694K added.
- The largest Grace Therapeutics seller in Q2 2026 was Nantahala Capital Management, an estimated $3.37M sold.
Based on aggregated 13F filings for Q2 2026.